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Effect of endogenous and exogenous EGF on the growth of EGF
receptor-hyperproducing human squamous cell carcinoma implanted in
nude mice
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Sunmnary The effect ofepidermal growth factor (EGF) on the biological behaviour ofhuman tumours in vivo
is still controversial. We investigated the effect of EGF on the growth of an EGF receptor-hyperproducing
human epidermoid carcinoma, A431 tumour, and on a human small-cell lung carcinoma, H69 tumour,
without detectable EGF receptor by using sialoadenectomised (sialex) mice as an endogenous EGF-suppressed
animal model. The plasma EGF concentration in the sialex athymic mice was significantly lower than that in
the sham-operated mice (P<0.05). After exogenous EGF replacement with an implanted minipump, the
plasma EGF concentration was significantly increased in both groups (P<0.05). There was no significant
difference betwee'the body weight growth curves of sialex and sham-operated mice with and without EGF
treatment. The tumour weight of A431, both estimated and measured in sialex mice, was significantly lower
than that in sham-operated control mice (P<0.05), and the growth of A431 tumour was significantly
increased by exogenous EGF treatment (P<0.05). Mitotic activity of these tumours detected by immunohis-
tochemical staining for incorporated bromodeoxyuridine indictated a mitosis-stimulatory effect of endogenous
and exogenous EGF on A431 tumours. In contrast to these findings on A431 tumours, a growth-stimulatory
effect of endogenous and exogenous EGF was not observed in the H69 tumour. These results suggest a
growth-promoting effect of physiological levels of endogenous EGF on EGF receptor-hyperproducing human
tumours in vivo.
Keywords: squamous cell carcinoma; epidermal growth factor; epidermal growth factor receptor; sialoadenec-
tomy; bromodeoxyuridine labelling index
Epidermal growth factor (EGF) was originally isolated from
a mouse submandibular gland (Carpenter and Cohen, 1979)
and has various biological actions as a potent mitogen for
the epidermis and several epithelial tissues (Hollenberg, 1979;
Das, 1982; Fox et al., 1982). Many transformed cells produce
EGF-associated growth factors, such as transforming growth
factor alpha (TGF-a) which interacts with EGF receptors,
and TGF-P (Sporn and Roberts, 1984). Overexpression of
EGF receptor has been shown to occur at a high incidence
both in primary squamous cell carcinomas and in established
cell lines such as A431 (Ozanne et al., 1985; Gullick et al.,
1986; Ozawa et al., 1987a). The v-erbB oncogene of avian
erythroblastosis virus originates from part of the host cell
EGF receptor gene (Ullrich et al., 1984; Shimizu et al., 1985).
Thus, the involvement of the EGF and its receptors in trans-
formation and progression of malignant cells has been sug-
gested. Although there are several studies investigating the
effect of EGF on the growth of EGF receptor-
hyperproducing cell lines in vitro and in vivo (Gill and Lazer,
1981; Kamata et al., 1986; Ozawa et al., 1987b; Amagase et
al., 1990; Murayama, 1990), the physiological role of EGF
on the EGF receptor-hyperproducing tumour growth re-
mains obscure and still controversial. Tsutsumi et al. (1987a)
demonstrated that EGF at the physiological level promotes
the implantation and growth of spontaneous mouse mam-
mary tumours in female nude mice. There have been no
previous studies on the effect of changes in plasma EGF
levels within the physiological range on the growth of human
tumours which have various EGF receptor levels. The mouse
submandibular gland is a rich source of EGF, and it is well
established that sialoadenectomy lowers the circulating level
of EGF in mice (Tsutsumi et al., 1986, 1987b). In this study,
we investigated the effect of endogenous EGF on EGF-




Mouse submandibular gland EGF was obtained from
Toyobo (Osaka, Japan). Bromodeoxyuridine (BrdU) and
anti-BrdU monoclonal antibodies were obtained from Ikeda
(Osaka) and Becton Dickinson (Mountain View, CA, USA),
respectively. Normal mouse IgG was obtained from Sigma
(St Louis, MO, USA). Alzet mini-osmotic pumps were
obtained from Alza (Palo Alto, CA, USA). '251-labelled EGF
(100 iCilg-1) was purchased from Amersham International
(Buckinghamshire, UK). All other reagents were ofanalytical
grade.
Cells and cell culture
The human epidermoid carcinoma cell line A431 was
obtained from the Japan Cancer Research Resource Bank.
The human small-cell lung carcinoma cell line H69 was
kindly given to us by Dr S Hirohashi. The cell lines were
maintained at 37°C in a humidified 5% carbon dioxide atmo-
sphere in Dulbecco's modified Eagle medium (DMEM) supp-
lemented with 10% fetal calf serum.
Animals and treatments
Male athymic mice (BALB/c nu/nu) were obtained from
Nisseiken, Oume (Tokyo, Japan), and were maintained in an
aseptic environment. The submandibular glands were
removed (or a sham operation was performed) from 5-week-
old male nude mice under ether anaesthesia. Two weeks after
the sialoadenectomy (sialex) or sham operation, tumour cells
were subcutaneously (s.c.) inoculated. Cells (A431 or H69) in
culture were detached by trypsinisation and washed with
serum-free DMEM. Cell suspensions of 1 x 108 cells in 150 tll
ofphosphate-buffered saline (PBS) were injected bilaterally in
the-abdominal region of the athymic mice. On the next day
Alzet mini-osmotic pumps containing 150 jig of mouse EGF
dissolved in physiological saline, or 200 ll of physiological
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saline, were implanted s.c. into the backs of athymic mice.
The rate of EGF administration was 7.5 ng of EGFmin-.
Body weight and tumour size were measured every day after
tumour cell inoculation. The tumour weight was estimated by
the following formula:
Tumour weight = longer diameter x shorter diameter2 x 0.5
On the 10th day after the inoculation of tumour cells, the
mice were sacrificed. Tumours were removed under sterile
conditions, weighed and stored at - 70°C until use. The mice
were divided into four groups: sialex only, sialex and EGF
replaced, sham operation only and sham-operation and EGF
replaced. Seven mice (14 tumours) were used for each
group.
Radioimmunoassav of EGF
Blood was collected in a heparinised syringe via the orbital
artery under ether anaesthesia. The blood samples were
chilled immediately to 4°C and centrifuged at 8700 g for
5 min, and the plasma was aspirated and stored at - 70°C
until assayed. Plasma EGF concentrations were determined
by radioimmunoassay using '25I-labelled EGF (Amersham).
BrdU staining
The excised tumours were examined for DNA replicating
cells by the avidin-biotin complex (ABC) method using
anti-BrdU monoclonal antibody. BrdU (25 mg kg-') was
injected into the peritoneal cavity of the mice 3 h before the
tumour removal. The excised tumours were fixed in 70%
ethanol, embedded in paraffin and cut into 4-pim sections.
The sections were deparaffinised, immersed in 2 M hydro-
chloric acid for 30 min to denature the DNA, and neutralised
by exposure to 0.1 M sodium borate for 10min. The sections
were then covered with 10% normal horse serum at room
temperature for 30 min, and incubated with anti-BrdU
monoclonal antibody (diluted 1: 100 with 10% normal horse
serum) at 4°C overnight. The subsequent steps were carried
out according to the usual ABC staining method. The sec-
tions were stained with diaminobenzidine (0.5 mg ml-') in
0.01% hydrogen peroxide. Normal mouse IgG was used as a
negative control. Labelling indices were obtained as follows:
nuclei of 2000 tumour cells were classified as labelled or
unlabelled. The labelling indices were then calculated from
the equation:
BrdU labelling index=
Number of labelled tumour cell nuclei
Number of tumour cell nuclei counted
x 100
Statistical analysis
Data were analysed by Student's t-test. A value of P<0.05
was considered significant.
Results
Effect of sialex on plasma EGF levels
The plasma EGF concentration in the sialex mice
(0.11 ± 0.03 ng ml-1) was significantly lower than that in the
sham-operated mice (2.15 ± 1.23 ng ml-') (P<0.05) (Figure
1). The plasma EGF levels in the sialex and sham-operated
mice were significantly increased by continuous EGF
administration. After the exogenous EGF replacement, there
was no significant difference between the plasma EGF levels
of the sialex (7.90 ± 1.81 ng ml-') and sham-operated mice
(8.67 ± 1.54 ng ml-') (Figure 1).
sham-operated control + EGF, sialex and sialex + EGF - are
shown in Figure 2. Increase in tumour weight in the sialex
mice was significantly suppressed compared with that in the
sham-operated control mice (P<0.05). In both the EGF-
treated sialex and EGF-treated sham-operated mice, growth
of the tumours was significantly increased (P<0.05). The
growth curves for H69 tumours in the four groups are shown
in Figure 3. There was no significant difference in estimated
tumour weight of these tumours among the four groups.
These findings on estimated tumour growth in A431 and H69
tumours were confirmed by weighing the tumours after they




















Figure 1 Effect of sialoadenectomy and EGF replacement by
minipump on plasma EGF levels. The plasma EGF concentra-
tions (mean ± s.e.) of sham-operated mice (sham op.), sialo-
adenectomised mice (sialex), mice with sialoadenectomy and EGF
replacement (sialex + EGF) and mice with sham operation and
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The growth curves for estimated tumour weight of A431
tumours in four different groups - sham-operated control,
Figure 2 Growth curves of the estimated tumour weight of the
A431 tumour transplanted into nude mice. Growth curves of the
estimated tumour weight of the A431 tumours transplanted into
nude mice with sham operation (0), sialoadenectomy (0), sham
operation and EGF replacement (A) and sialoadenectomy and
EGF replacement (A) are shown. *P<0.05.
A _m 0= "W"
866Effect ofsialex and exogenous EGF replacement on mitotic
activity of tumour cells detected by BrdU staining
Tumour cells that had incorporated BrdU into DNA were
detected by immunohistochemical staining using anti-BrdU
monoclonal antibody. BrdU labelling indices of A431 and
H69 tumours in these four groups are indicated in Table II.
The BrdU labelling index of A431 tumours in the sialex mice
was lower (not significantly) than that in the sham-operated
control mice. BrdU labelling indices of EGF-treated sialex
and sham-operated mice were significantly higher than that
in the sham-operated control mice (P <0.05). On the other
hand, there was no significant difference in the BrdU labell-
ing indices of H69 tumours among the four groups, as shown
in Table II.
Discussion
Early studies on the effects of EGF on the growth of EGF
receptor-hyperproducing squamous carcinoma cell lines in
culture, including A431 cells, have demonstrated a growth-
inhibitory effect of EGF on these cell lines (Gill and Laser,
1981; Kamata et al., 1986). Although KUI, a human bladder
carcinoma cell line established from a high-grade transitional
cell carcinoma, had an elevated number of EGF receptors
compared with A431, anchorage-dependent growth of KUI










Figure 3 Growth curves of the estimated tumour weight of the
H69 tumour transplanted into nude mice. Growth curves of the
estimated tumour weight of the H69 tumours transplanted into
nude mice with sham operation (0), sialoadenectomy (0), sham
operation and EGF replacement (A) and sialoadenectomy and
EGF replacement (A) are shown.
Table I Tumour weight (g) at sacrifice of the four groups on the
10th day after subcutaneous inoculation of tumour cells
Sialex Sialex + EGF Sham op. Sham op. + EGF
A431 1.76 0.23 4.35 ± 0.43 2.95 ± 0.33 4.41 ± 0.47
H69 0.19 ± 0.19 0.22 ± 0.23 0.17 ± 0.36 0.20 ± 0.42
*P< 0.0.
Table II BrdU labelling indicesa in tumours implanted into athymic
mice
Sialex Sialex + EGF Sham op. Sham op. + EGF
r ** -I I *
A431 4.2 ± 2.5 13.1 ± 3.2 5.6 ± 2.1 15.5 ± 3.1
H69 2.0± 1.9 1.9± 1.5 1.5±0.9 2.2± 1.7
aBrdU labelling index = (Number of labelled tumour cell
nuclei/Number of tumour cell nuclei counted) x 100. **P<0.05.
Proliferative effect of endogenous EGF in vivo
Y Kitagawa et al
867
growth of KU1 was stimulated by EGF (Ishikawa et al.,
1989). Previously, Lee et al. (1990) have demonstrated that
EGF inhibits anchorage-dependent growth but stimulates
anchorage-independent growth of human squamous car-
cinoma cell lines that overexpress EGF receptors. These
studies suggest that the proliferative responses of EGF
receptor-hyperproducing cells to EGF might be affected by
other characteristics of cell lines and culture conditions. It
seems that there are many factors which can affect the pro-
liferative responses to EGF in vivo, such as interaction with
interstitial tissues and other mediators. As Fidler (1990) dem-
onstrated in studies on mechanisms of cancer metastasis, the
outcome of metastasis depends on the interaction of metas-
tatic cells with different organ environments. Accordingly,
from this point of view, studies of 'the in vivo environment'
are important for the investigation of actual phenomena in
human carcinogenesis and progression.
However, the effect of EGF on the proliferation of EGF
receptor-hyperproducing tumours in vivo is still complicated
and controversial. Murayama (1990) has reported the
growth-inhibitory effects of EGF on human breast cancer
and oesophageal cancer cells transplanted into athymic mice,
and proposes the efficacy of EGF therapy for human cancers
with overexpression of EGF receptor. Amagase et al. (1990)
observed prolongation of the survival time of mice bearing
various murine syngeneic tumours as well as athymic mice
bearing human xenografts. On the other hand, Ginsburg and
Vonderhaar, (1985) and Ozawa et al. (1989) demonstrated
that EGF promotes the growth of tumours of EGF receptor-
hyperproducing squamous carcinoma cells.
The studies cited above indicate that differences in the
responses of EGF receptor-hyperproducing tumours to
exogenous EGF might depend on the doses and routes of
EGF administration. In this study, we have demonstrated the
proliferative effects of endogenous EGF at a physiological
level on the EGF receptor-hyperproducing human squamous
carcinoma cells transplanted to athymic mice. The growth-
inhibitory effect of sialex and growth-stimulatory effect of
exogenous continuous EGF administration on EGF receptor-
hyperproducing A431 tumours and the lack of an effect on
EGF receptor-undetectable H69 tumours clearly imply a role
of the EGF-EGF receptor system in the proliferation of
EGF receptor-overexpressing human tumours. On the other
hand, when EGF was administered as a local bolus injection
directly into the tumour (Murayama, 1990), this induced
down-regulation of the EGF receptor and did not reflect the
physiological role of endogenous EGF. Also, Amagase et al.
(1990) noted that prolongation of survival times by EGF is
independent of the number of EGF receptors on tumour
cells. The growth-inhibitory effects observed in these studies
apparently depend on mechanisms other than the
EGF-EGF receptor system. Tsutsumi et al. (1987a), how-
ever, demonstrated the promoting effect of a physiological
level of EGF on the implantation and growth of a mouse
mammary tumour in sialex nude mice. This is in agreement
with our data, which are the first to demonstrate the growth-
promoting effect of endogenous EGF on a human tumour
using a sialex nude mice model.
In this study, the BrdU labelling indices in these tumours
suggest that EGF promotes the mitotic activity of EGF
receptor-hyperproducing tumours. Changes in tumour weight
and BrdU labelling indices corresponded to the plasma EGF
level only in the EGF receptor-hyperproducing A431 cell
tumour. It is conceivable that physiological levels of EGF
contribute to the activation of the signal transduction path-
way that initiates cell proliferation.
Previously, squamous carcinomas of the neck, lung, gin-
giva and oesophagus were found to express elevated levels of
EGF receptors at high frequency (Ozanne et al., 1985; Gul-
lick et al., 1986; Ozawa et al., 1987a). Notably, in
oesophageal squamous cell carcinoma, a significant correla-
tion between the EGF receptor overexpression and poor
prognosis of the disease has been reported (Ozawa et al.,
1989). Amplification of the EGF receptor gene, c-erbB, was
significantly correlated with lymph node metastasis andProliferative effect of endogenous EGF in Wivo
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poorer prognosis in patients with oesophageal squamous cell
carcinoma (Kitagawa et al., 1992). Moreover, EGF expres-
sion has been detected in several human cancer cells, includ-
ing squamous cell carcinoma. Our observations in this study
suggest that EGF receptor-hyperproducing carcinomas in
patients have growth advantages through the EGF-EGF
receptor system, including the autocrine loop.
On the basis of such findings, Hirota et al. (1989) have
demonstrated the inhibitory effect of an immunotoxin, which
is the conjugated form of anti-EGF receptor monoclonal
antibody and plant toxin, to the A431 tumours transplanted
in athymic mice as a model of the anti-EGF-EGF receptor
system treatment. The findings shown in this study also are
encouraging for the establishment of anti-EGF-EGF recep-
tor system treatments for EGF receptor-hyperproducing
human cancers.
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